Home/Filings/4/0001104659-19-032920
4//SEC Filing

Novartis Bioventures Ltd 4

Accession 0001104659-19-032920

CIK 0001761612other

Filed

May 29, 8:00 PM ET

Accepted

May 30, 9:27 PM ET

Size

18.2 KB

Accession

0001104659-19-032920

Insider Transaction Report

Form 4
Period: 2019-05-28
Transactions
  • Conversion

    Ordinary Shares

    2019-05-28+893,195893,195 total
  • Conversion

    Ordinary Shares

    2019-05-28+636,3661,601,011 total
  • Purchase

    Ordinary Shares

    2019-05-28$14.00/sh+168,630$2,360,8201,769,641 total
  • Conversion

    Series B1 Preferred Shares

    2019-05-28636,3660 total
    Ordinary Shares (636,366 underlying)
  • Exercise of In-Money

    Ordinary Shares

    2019-05-28+71,450964,645 total
  • Conversion

    Series A Preferred Shares

    2019-05-28893,1950 total
    Ordinary Shares (893,195 underlying)
  • Exercise of In-Money

    Series A Preferred Shares Warrants

    2019-05-2871,4500 total
    Ordinary Shares (71,450 underlying)
NOVARTIS AG
10% Owner
Transactions
  • Conversion

    Series B1 Preferred Shares

    2019-05-28636,3660 total
    Ordinary Shares (636,366 underlying)
  • Conversion

    Ordinary Shares

    2019-05-28+893,195893,195 total
  • Exercise of In-Money

    Series A Preferred Shares Warrants

    2019-05-2871,4500 total
    Ordinary Shares (71,450 underlying)
  • Conversion

    Ordinary Shares

    2019-05-28+636,3661,601,011 total
  • Purchase

    Ordinary Shares

    2019-05-28$14.00/sh+168,630$2,360,8201,769,641 total
  • Conversion

    Series A Preferred Shares

    2019-05-28893,1950 total
    Ordinary Shares (893,195 underlying)
  • Exercise of In-Money

    Ordinary Shares

    2019-05-28+71,450964,645 total
Footnotes (2)
  • [F1]Each Series A and B1 Preferred Share automatically converted into Ordinary Shares on a one-for-1.429 basis upon the closing of the Issuer's initial public offering and had no expiration date.
  • [F2]Upon conversion of all of the Series B1 Preferred Shares into Ordinary Shares in connection with the Issuer's initial public offering, the Warrants became exercisable for Ordinary Shares. The Warrants had an exercise price of a nominal value per share and were exercised immediately prior to completion of the Issuer's initial public offering.

Documents

1 file

Issuer

BICYCLE THERAPEUTICS plc

CIK 0001761612

Entity typeother
IncorporatedBermuda

Related Parties

1
  • filerCIK 0001297709

Filing Metadata

Form type
4
Filed
May 29, 8:00 PM ET
Accepted
May 30, 9:27 PM ET
Size
18.2 KB